{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:55:53Z","timestamp":1779216953323,"version":"3.51.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize the spectrum, strength, and cross-database reproducibility of peripheral nervous system (PNS) safety signals associated with antibody\u2013drug conjugates (ADCs), and to examine discrepancies between post-marketing pharmacovigilance signals and current regulatory labeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multi-database pharmacovigilance study was conducted using spontaneous adverse event reports from the FDA Adverse Event Reporting System (FAERS; Q1-2025Q3), the Japanese Adverse Drug Event Report (JADER; 2004Q1\u20132025 Q3), and the Canada Vigilance Adverse Reaction Database (CVARD; January 1965 - October 2025). PNS-related adverse events were identified using the MedDRA Standardised MedDRA Query \u201cPeripheral neuropathy,\u201d supplemented by expert-curated preferred terms. Disproportionality analyses were performed using the reporting odds ratio, proportional reporting ratio, empirical Bayes geometric mean, and information component. Safety signals detected in FAERS were evaluated for reproducibility in JADER and CVARD and compared with PNS events described in current prescribing information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 31,592 post-marketing reports in which an ADC was recorded as the primary suspect were identified in FAERS, of which 1,395 involved PNS-related adverse events. A broad spectrum of PNS toxicities was observed, with peripheral neuropathy, polyneuropathy, peripheral sensory neuropathy, and peripheral sensorimotor neuropathy being the most frequently reported phenotypes. Consistent and robust associations were observed across all three databases, with reporting odds ratios of 4.62 (95% confidence interval [CI] 4.39\u20134.87) in FAERS, 42.84 (95% CI 39.56\u201346.40) in JADER, and 20.79 (95% CI 18.12\u201323.85) in CVARD. Rare but clinically severe neuropathic conditions, including Guillain\u2013Barr\u00e9 syndrome and chronic inflammatory demyelinating polyradiculoneuropathy, also met predefined signal-detection criteria. Time-to-onset analyses demonstrated substantial heterogeneity, with median onset occurring within approximately 20\u201340 days for several ADCs, whereas delayed presentations beyond 80\u2013100 days were observed for others. A large proportion of PNS reports were classified as serious, most commonly involving hospitalization. Notably, several PNS signals identified through post-marketing surveillance were not consistently described in current prescribing information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This multi-database pharmacovigilance analysis identified robust and reproducible PNS safety signals associated with ADCs, including clinically relevant events not uniformly described in current regulatory labeling. These findings are hypothesis-generating and support signal prioritization rather than causal inference, underscoring the importance of ongoing post-marketing surveillance to inform regulatory awareness and risk communication as ADC use continues to expand.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1786431","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:35:39Z","timestamp":1776749739000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Peripheral nervous system safety signals of antibody\u2013drug conjugates: cross-database reproducibility and labeling gaps identified using FAERS, JADER, and CVARD"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaojie","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yabin","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hebei Children\u2019s Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liman","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the US FDA adverse event reporting system (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with Brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"115534","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"21386","DOI":"10.1038\/s41598-024-71977-0","article-title":"Pharmacovigilance study of the association between peripheral neuropathy and antibody\u2013drug conjugates using the FDA adverse event reporting system","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40264-021-01142-3","article-title":"Sources of evidence triggering and supporting safety-related labeling changes: a 10-year longitudinal assessment of 22 new molecular entities approved in 2008 by the US Food and Drug administration","volume":"45","author":"Croteau","year":"2022","journal-title":"Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2024-106229","article-title":"Global estimates of prevalence of chronic painful neuropathy and moderate-to-severe neuropathy among patients with chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of data from 29 countries between 2000 and 2024","volume":"4","author":"D\u2019Souza","year":"2025","journal-title":"Reg. Anesth. Pain Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cpt.2083","article-title":"Randomized controlled trials versus real-world evidence: neither magic nor myth","volume":"109","author":"Eichler","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B14","unstructured":"Guideline on good pharmacovigilance practices (GVP): Module IX\u2013Signal management (Rev. 1)\n          \n          \n          2017"},{"key":"B15","doi-asserted-by":"publisher","first-page":"107778","DOI":"10.1016\/j.isci.2023.107778","article-title":"Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates","volume":"26","author":"Fu","year":"2023","journal-title":"iScience"},{"key":"B16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"","journal-title":"Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for drUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"","journal-title":"Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-world data task force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"n1959","DOI":"10.1136\/bmj.n1959","article-title":"Regulatory and clinical consequences of negative confirmatory trials of accelerated approvals for cancer drugs","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","article-title":"Defining \u2018signal\u2019 and its subtypes in pharmacovigilance","volume":"32","author":"Hauben","year":"2009","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/pds.4446","article-title":"Characteristics of drug safety signals that predict safety-related product information update","volume":"27","author":"Insani","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody\u2013drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody\u2013drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant acute myeloid leukemia","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.3390\/cancers16142571","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): a narrative review and proposed theoretical model","volume":"16","author":"Lee","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: a systematic review","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B28","unstructured":"Introductory guide for standardised MedDRA queries (SMQs), version 27.1\n          \n          \n          2025"},{"key":"B29","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC, demonstrates a promising therapeutic profile","volume":"22","author":"Ogitani","year":"","journal-title":"Clin. Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"","journal-title":"Cancer Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1158\/1078-0432.CCR-14-0521","article-title":"Design of phase I combination trials: recommendations of the clinical trial design task force of the NCI investigational drug steering committee","volume":"20","author":"Paller","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMp1401111","article-title":"Learning from big health care data","volume":"370","author":"Schneeweiss","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab vedotin: a review in CD30-Positive hodgkin lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-Positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann. Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"B43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1362484","DOI":"10.3389\/fphar.2024.1362484","article-title":"A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)","volume":"15","author":"Tang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"B46","unstructured":"FDA adverse event reporting system (FAERS)\n          \n          \n          2025"},{"key":"B47","unstructured":"Drugs@FDA: FDA-approved drugs\n          \n          \n          2026"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B49","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","article-title":"Good signal detection practices: evidence from IMI PROTECT","volume":"39","author":"Wi\u015bniewski","year":"2016","journal-title":"Drug Saf."},{"key":"B50","doi-asserted-by":"publisher","first-page":"oyaf298","DOI":"10.1093\/oncolo\/oyaf298","article-title":"Adverse events of antibody-drug conjugates: comparative analysis of agents with a common payload using the adverse event spontaneous reporting database","volume":"30","author":"Yamaoka","year":"2025","journal-title":"Oncologist"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1786431\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:35:44Z","timestamp":1776749744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1786431\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":50,"alternative-id":["10.3389\/fphar.2026.1786431"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1786431","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1786431"}}